AI-biotech firm Owkin has announced MSIntuit CRC v2, a next-generation AI solution aimed at transforming the detection and treatment of colorectal cancer (CRC). It will initially launch in the US as research use only, on Roche’s navify digital pathology enterprise software.
MSIntuit CRC v2 builds upon the success of the CE-IVD-certified MSIntuit CRC, integrating cutting-edge machine learning models developed by Owkin with Roche's expertise in oncology diagnostics. MSIntuit CRC v2 will incorporate analysis from resections, and now biopsies, addressing a critical need within pathologists’ workflows.
This latest version features a new architecture with advanced machine learning models significantly enhancing model performance. It also introduces improved staining techniques, including haematoxylin and eosin (H&E) and haematoxylin, eosin and saffron (HES), further refining the accuracy and reliability of the product, and expanding access of the solution to more laboeatories
Meriem Sefta PhD, Chief Diagnostics Officer of Owkin, said: “We are thrilled to bring the next innovations in MSIntuit CRC to pathology laboratories, marking a significant advancement in the field of medical diagnostics. This innovation represents our commitment to pushing the boundaries of artificial intelligence in healthcare. By leveraging cutting-edge AI technology, we aim to provide more accurate diagnostic tools that will empower pathologists and oncologists to make more informed decisions. Our goal is to help deliver highly personalised treatment plans, improving patient outcomes and ensuring that each individual receives the most precise care tailored to their unique medical needs. This is just one step forward in transforming the future of patient care through technology-driven solutions and we look forward to expanding our collaboration with Roche Diagnostics in pursuit of this essential mission.”
These tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling targeted treatments. The RUO version of MSIntuit CRC v2 will soon be available in the US on Roche’s navify software, with additional platforms to come.